Citations

Clear

89 citation(s) found for "Davis, John".

Phase 2 study of MGTA-145 + plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.
Sidana, Surbhi , Bankova, Andriyana K. , Hosoya, Hitomi , Muffly, Lori , Kumar, Shaji , Johnston, Laura, Lowsky, Robert , Meyer, Everett , Rezvani, Andrew R. , Weng, Wen‐Kai , Arai, Sally , Frank, Matthew J. , Howell, Haley, Goncalves, Kevin A, Schmelmer, Veit, Davis, John C. , Shizuru, Judith A. , Miklos, David B. , Sidana, Surbhi , Miklos, David B , Muffly, Lori , Hosoya, Hitomi , Shiraz, Parveen , Goncalves, Kevin A, Davis, John

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 8023-8023

10.1200/jco.2021.39.15_suppl.8023 Get It

8023 Background: MGTA-145 (GroβT), a CXCR2 agonist, has shown promising activity for HSC mobilization with plerixafor in pre-clinical models and healthy volunteers. Methods: This phase 2 single center study evaluates HSC mobilization with MGTA-145 + plerixafor and same day apheresis in patients with multiple myeloma. Patients received plerixafor 0.24 mg/kg (0.16 mg/kg if renal dysfunction) SQ, followed 2 hours later by MGTA-145 (0.03 mg/kg) IV over 3-10 minutes and apheresis within 30 minutes. Mobilization was repeated for a second day if day 1 yield was < 6 x 106 CD34+ cells/kg. This interim analysis reports on mobilization in 10 patients (of 25 planned), including safety cohort of first 6 patients completing transplant. Primary endpoint is collection of 2 x 106 CD34+ cells/kg. Results: Median age was 63 years (range: 46-68), 50% were female, 22% had ISS stage 3 & 50% had high-risk FISH. Induction therapy was VRD in 7 and daratumumab + VRD in 3 patients; median induction duration: 4 months (3-6) & median lenalidomide exposure: 6 cycles (4-6), with > VGPR in 70%. Median total stem cell yield (CD34+ cells/kg x 106) was 7.1 (3-16.2), day 1 yield was 5.4 (1.1-16.2) & yield per apheresis session was 4 (1.1-16.2). 100% of patients met the primary endpoint of collecting sufficient HSCs in < 2 days of mobilization + apheresis to proceed to transplant (2 x 106 CD34+ cells/kg). Secondary endpoints of 4 and 6 x 106 CD34+ cells/kg in < 2 days were met in 90% & 80% patients. 30% patients underwent 1 apheresis, while 70% underwent 2 sessions. MGTA-145 was well tolerated. At least 1 adverse event (AE) was seen in 90% of patients, 20% had grade 2 AEs (anemia, hypokalemia) and 20% had grade 3 AEs (worsening of baseline grade 3 anemia; hypocalcemia); all resolved. Acute & transient bone pain was seen in 40% of patients (back-2, hip-1, sternum-1), all grade 1, all on day 1, & resolved without intervention after 6 minutes (3-10). All 6 patients in the safety cohort have completed transplant with melphalan 200 mg/m2. Median of 4.1 (3.4-5.6) x 106 CD34+ cells/kg were infused. All patients have engrafted timely (DiPersio Blood 2009); median time to neutrophil engraftment: 12 days (11-13) & platelet engraftment: 17 days (16-19). Apheresis graft analysis is available in these 6 patients. Grafts with MGTA-145+plerixafor showed high enrichment for CD90+CD45RA- among CD34+ cells, a CD34 subset of long term engrafting HSCs (median: 31% of CD34+ cells, 27-52), higher than seen with G-CSF (6%, Goncalves TCT 2021). 67% of grafts were minimal residual disease negative with next generation flow cytometry. Conclusions: This is the first study to evaluate the novel regimen of MGTA-145 + plerixafor for same day stem cell mobilization & collection in myeloma/hematologic malignancies, with 100% efficacy in interim analysis and the first to demonstrate successful engraftment in patients with cells collected with this GCSF free regimen. Clinical trial information: NCT04552743.
Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis
Paknikar, Sujaytha S. , Crowson, Cynthia S. , Davis, John M. , Thanarajasingam, Uma , Davis, John M

Mayo Clinic

ACR Open Rheumatology | June 1, 2021 | Volume: 3 | Issue: 6 | Pages: 422-426

10.1002/acr2.11271 | PMID 34060254 Get It

ObjectiveThe objective of this study was to describe differences in the clinical course of patients with rheumatoid arthritis (RA) who are antinuclear antibody (ANA)–positive compared with those who are ANA‐negative.MethodsThis was a retrospective population‐based cohort study of residents in Olmsted County, Minnesota, who first fulfilled 1987 American College of Rheumatology criteria for RA in 2009‐2014. Data were collected on first documentation of joint swelling. Data on rheumatoid factor or anti‐cyclic citrullinated peptide antibody testing and the ANA level were also collected. Comparisons between groups were performed by using χ2 and rank sum tests.ResultsIn this cohort, 64% of patients were tested for ANA within ±90 days of RA criteria fulfillment. In the161 patients with ANA testing, 25% were ANA‐positive. Patients who were ANA‐positive were younger, female, and less likely to be current smokers. ANA positivity did not differ between patients with RA who were seropositive and seronegative. In seropositive patients who were ANA‐positive, there was an increased time to fulfillment of RA criteria, increased time to treatment with disease‐modifying antirheumatic drugs (DMARDs), and increased likelihood of being treated with hydroxychloroquine as opposed to methotrexate. Other outcomes, including disease activity and mortality, did not differ significantly between groups.ConclusionIn patients with RA, important differences exist between those who are ANA‐positive and ANA‐negative in terms of time to fulfillment of RA criteria and time to DMARD initiation as well as choice of initial pharmacotherapy. These findings could indicate a difference in clinical presentation or perception of patients with RA who are ANA‐positive. Further research is needed to study the long‐term outcomes of patients with RA who are ANA‐positive.
Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up
Heuer, Dale K. , Higginbotham, Eve J. , Parrish, Richard , Khanna, Cheryl L. , Brandt, James D. , Soltau, Joern B., Keltner, John L., Huecker, Julia B., Wilson, Bradley , Gordon, Mae O. , Group, Ocular Hypertension Study, Gedee, Steven J., Esquiabro, Maria, Fabrizio, Matthew J., Patorgis, Charles J., Long, Teresa A., McManus, Paul E., Washington, Chantura, Chang, Peter , Orengo-Nania, Silvia, Leger, April, Kinast, Robert M. , Jones, Emily P., Goldman, Casie, Beck, Allen D. , Costarides, Anastasios P., Leef, Donna, Imami, Nauman R., Darnley-Fisch, Deborah , Crandall, David, Gutkowski, Melanie, Hall, Julianne, Fantin, Aldo, Wells, Judy, Jampel, Henry , Quigley, Harry A., Miller, Rhonda, Kalarn, Sachin , Coleman, Anne L. , Young, Jonathan W., Peterson, Christine A., Giaconi, JoAnn A. , Law, Simon K., Duarte, Pamela B., Wood, Sarah Dougherty , Moroi, Sayoki, Gilbert, Jesse L., Shukairy, Aman, Juzych, Mark S. , Milanovic, Cheryl, O'Grady, John M., Conett, Linda A. Van, Mohay-Ambrus, Judith, Bottorff, Michelle, Bennett, Jeffrey R., Sultze, Jane L., Patel, Dharmendra, Cobb, Steven H., Bhattacharjee, Pompa, Cioffi, George A., Blumberg, Dana M., Moraes, Carlos Gustavo De , Atakulova, Marzhan, Weber, Paul A., Sawchyn, Andrea K., Williams, Demarcus, Bennett, George, Bennett, Lindsay C., Miller-Ellis, Eydie , Sankar, Prithvi S. , Grand-Drossner, Sheri, Piltz‐Seymour, Jody R., Niemczyk, Jane L., Brandt, James D., Lim, Michelle, Balasubramaniam, Saranya C., Baik, Annie K., Arnold, Marisa S., Slight, J. Rigby, Ou, Yvonne , Lamping, Kathleen A., Vitelli, Cheryl L., Ashburn, Frank S., Hardney, Karen S., Schwartz, Arthur L., Weiss, Howard S., Clark, Clete, Bhorade, Anjali M., Lind, John T., Adcock, Eve, Plumb, Kim, Leming, Laura, Dillon, B A, Palmberg, Paul, Hodapp, Elizabeth, Varner, Elizabeth A., Savatovsky, Eleonore , Vandenbroucke, Ruth, Dirkes, Keri , Vega, Suzanne , Hunsicker, Maria, Proudfoot, J. , Dunn, D, Everett, Donald F., Gutowski, Melanie, Fischbach, Ellen, Clark, Karen A., Morris, Patricia A., Quinn, Melanie, Pistorius, Sam, Haertter, Leonard W., Kass, Michael A. , Johnson, Chris A. , Liu, Lei , Miller, J. Philip , Quigley, Harry A. , Group, Ocular Hypertension Study, Patorgis, Charles J., Washington, Chantura, Mansberger, Steven L. , Wells, Judy, Quigley, Harry A., Saeedi, Osamah J. , Hughes, Bret A. , Liebmann, Jeffrey M. , Al‐Aswad, Lama A. , Brandt, James D., Lim, Michelle C., Weinreb, Robert Neal , Smith, Mike A., Feuer, William J. , Zangwill, Linda M. , Morris, Patricia A.

Mayo Clinic

JAMA Ophthalmology | April 17, 2021 | Volume: 139 | Issue: 5 | Pages: 558

10.1001/jamaophthalmol.2021.0341 | PMID 33856434 Get It

The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population‐Based Study
Karmacharya, Paras , Crowson, Cynthia S. , Bekele, Delamo I. , Achenbach, Sara J., Davis, John M. , Duarte‐García, Alí , Ernste, Floranne C. , Kremers, Hilal Maradit , Tollefson, Megha M. , Wright, Kerry , Bekele, Delamo , Duarte-García, Alí , Maradit-Kremers, Hilal, Davis, John M , Karmacharya, Paras , Maradit Kremers, Hilal , Ogdie, Alexis

Mayo Clinic

Arthritis & Rheumatology | March 29, 2021 | Volume: 73 | Issue: 10 | Pages: 1878-1885

10.1002/art.41741 | PMID 33779070 Get It

ObjectiveTo determine the incidence of psoriatic arthritis (PsA) in a US population and describe trends in incidence and mortality over 5 decades.MethodsThe previously identified population‐based cohort that included Olmsted County, Minnesota residents ≥18 years of age who fulfilled PsA criteria during 1970–1999 was extended to include patients with incident PsA during 2000–2017. Age‐ and sex‐specific incidence rates and point prevalence, adjusted to the 2010 US White population, were reported.ResultsThere were 164 incident cases of PsA in 2000–2017 (mean ± SD age 46.4 ± 12.0 years; 47% female). The overall age‐ and sex‐adjusted annual incidence of PsA per 100,000 population was 8.5 (95% confidence interval [95% CI] 7.2–9.8) and was higher in men (9.3 [95% CI 7.4–11.3]) than women (7.7 [95% CI 5.9–9.4]) in 2000–2017. Overall incidence was highest in the 40–59 years age group. The incidence rate was relatively stable during 2000–2017, with no evidence of an overall increase or an increase in men only (but a modest increase of 3% per year in women), compared to 1970–1999 when a 4%‐per‐year increase in incidence was observed. Point prevalence was 181.8 per 100,000 population (95% CI 156.5–207.1) in 2015. The percentage of women among those with PsA increased from 39% in 1970–1999 and 41% in 2000–2009 to 54% in 2010–2017 (P = 0.08). Overall survival in PsA did not differ from the general population (standardized mortality ratio 0.85 [95% CI 0.61–1.15]).ConclusionThe incidence of PsA in this predominantly White US population was stable in 2000–2017, in contrast to previous years. However, an increasing proportion of women with PsA was found in this study.
Why women have more autoimmune diseases than men: An evolutionary perspective
Kronzer, Vanessa L. , Bridges, S. Louis , Davis, John M. , Kronzer, Vanessa L , Davis, John M

Mayo Clinic

Evolutionary Applications | November 15, 2020 | Volume: 14 | Issue: 3 | Pages: 629-633

10.1111/eva.13167 | PMID 33767739 Get It

AbstractWomen have up to a fourfold increase in risk for autoimmune disease compared to men. Many explanations have been proposed, including sex hormones, the X chromosome, microchimerism, environmental factors, and the microbiome. However, the mechanism for this autoimmune sex bias remains obscure. In this manuscript, we evaluate the hypothesis that qualitative or quantitative differences in circulating antibodies may explain, at least in part, the pathogenesis of autoimmune disease and its sex bias—especially when considering an evolutionary perspective. Indeed, women have higher absolute levels of antibodies than men, and (auto)antibodies are also associated with most autoimmune diseases. Several facts suggest differences in antibodies may cause increased prevalence of autoimmune disease in women. First, the association between increased quantities of serum antibodies and increased prevalence of autoimmunity is found not only in women, but also in men with Klinefelter syndrome. Second, both serum antibody levels and autoimmunity spike in the postpartum period. Third, a dose–response effect exists between parity and both serum antibodies and prevalence of autoimmune disease. Fourth, many biologically plausible mechanisms explain the association, such as T cell‐dependent activation of B cells and/or VGLL3. The evolutionary underpinning of increased antibodies in women is likely to be protection of offspring from infections. Overall, this evolutionary paradigm can help explain why the phenomenon of autoimmunity occurs preferentially in women and raises the possibility of new treatment options.
Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019
Bansal, Pankaj , Goyal, Amandeep , Cusick, Austin , Lahan, Shubham , Bhyan, Poonam , Bhattad, Pradnya Brijmohan , Sanghavi, Devang , Sonani, Bhavin, Davis, John M. , Aslam, Fawad , Chhabra, Lovely , Bansal, Pankaj , Davis, John M , Dhaliwal, Harpal S. , Ranka, Sagar , Dalia, Tarun

Mayo Clinic

Annals of Medicine | October 23, 2020 | Volume: 53 | Issue: 1 | Pages: 117-134

10.1080/07853890.2020.1839959 | PMID 33095083 Get It

Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate
Hall, William A. , Fishbane, Nick , Xu, Melody, Davicioni, Elai , Den, Robert B. , Dess, Robert T. , Wong, Anthony , Schaeffer, Edward M. , Karnes, R. Jeffrey , Kim, Hyung L. , Klein, Eric A. , Davis, John W. , Ross, Ashley E. , Tosoian, Jeffrey J. , Mehra, Rohit , Salami, Simpa S. , Nguyen, Paul L. , Lawton, C.A., Spratt, Daniel E. , Feng, Felix Y. , Xu, Melody J , Davicioni, Elai , Den, Robert B , Dess, Robert T , Jackson, William C , Wong, Anthony C , Carroll, Peter R , Bismar, Tarek A , Kim, Hyung L , Klein, Eric A , Tosoian, Jeffrey J , Morgan, Todd M , Salami, Simpa S , Spratt, Daniel E , Liu, Yang , Mahal, Brandon A. , Jackson, Will , Cooperberg, Matthew R , Morgan, Todd M.

Mayo Clinic

JCO Precision Oncology | October 16, 2020 | Volume: No volume available | Issue: 4 | Pages: 1228-1238

10.1200/po.20.00013 | PMID 35050780 Get It

PURPOSE Pretreatment estimates of seminal vesicle invasion (SVI) are challenging and significantly influence the management of prostate cancer. We sought to improve current models to predict SVI through the development of an SVI prediction genomic signature. PATIENTS AND METHODS A total of 15,889 patients who underwent radical prostatectomy (RP) with available baseline clinical, pathology, and transcriptome data were retrieved from the GRID registry (ClinicalTrials.gov identifier: NCT02609269 ) and other retrospective cohorts. These data were divided into a training (n = 6,766), test (n = 3,363), and two validation (n = 5,062 and 698) cohorts. Multivariable logistic regression was performed to assess the predictive effect of the genomic SVI (gSVI) classifier in the presence of established nomograms (Partin Tables and Memorial Sloan Kettering Cancer Center [MSKCC]). RESULTS In the training cohort, univariable filtering identified 2,132 genes that were differentially expressed between RP tumors with and without SVI. Model parameters were tuned to maximize the area under the curve (AUC) in the testing cohort, resulting in a logistic generalized linear model with 581 genes. The gSVI model scores range from 0 to 1. In the first validation set, gSVI showed superior discrimination of patients with and without SVI at RP compared with other prognostic signatures trained to predict distant metastasis or clinical recurrence. Of the 698 patients in the second validation set, gSVI combined with the MSKCC nomogram had a superior AUC (0.86) compared with either nomogram individually (0.81). CONCLUSION The gSVI represents a novel and validated expression signature to predict the presence of SVI before treatment with surgery. This genomic tool adds discriminatory power to existing clinical predictive nomograms and may help with pretreatment counseling and decision making.
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia
Scholand, Mary Beth , Lynch, David A. , Colby, Thomas V. , Groshong, Steve D. , Benzaquen, Sadia , Nathan, Steven D. , Davis, John R., Schmidt, Shelley L., Hagmeyer, Lars , Sonetti, David A., Hetzel, Jürgen, Case, Amy Hajari , Ramaswamy, Murali, Calero, Karel , Gauhar, Umair, Lancaster, Lisa , Choi, Yoonha, Pankratz, Daniel G., Walsh, P. Sean, Lofaro, Lori , Huang, Jing , Bhorade, Sangeeta , Kennedy, Giulia C., Raghu, Ganesh , Richeldi, Luca , Myers, Jeffrey L. , Chung, Jonathan Hero , Davis, J. Russell, Criner, Gerard J. , Patel, Nina , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 28, 2020 | Volume: 203 | Issue: 2 | Pages: 211-220

10.1164/rccm.202003-0877oc | PMID 32721166 Get It

Abstract Rationale Usual interstitial pneumonia (UIP) is the defining morphology of idiopathic pulmonary fibrosis (IPF). Guidelines for IPF diagnosis conditionally recommend surgical lung biopsy for histopathology diagnosis of UIP when radiology and clinical context are not definitive. A “molecular diagnosis of UIP” in transbronchial lung biopsy, the Envisia Genomic Classifier, accurately predicted histopathologic UIP. Objectives We evaluated the combined accuracy of the Envisia Genomic Classifier and local radiology in the detection of UIP pattern. Methods Ninety-six patients who had diagnostic lung pathology as well as a transbronchial lung biopsy for molecular testing with Envisia Genomic Classifier were included in this analysis. The classifier results were scored against reference pathology. UIP identified on high-resolution computed tomography (HRCT) as documented by features in local radiologists’ reports was compared with histopathology. Measurements and Main Results In 96 patients, the Envisia Classifier achieved a specificity of 92.1% (confidence interval [CI],78.6–98.3%) and a sensitivity of 60.3% (CI, 46.6–73.0%) for histology-proven UIP pattern. Local radiologists identified UIP in 18 of 53 patients with UIP histopathology, with a sensitivity of 34.0% (CI, 21.5–48.3%) and a specificity of 96.9% (CI, 83.8–100%). In conjunction with HRCT patterns of UIP, the Envisia Classifier results identified 24 additional patients with UIP (sensitivity 79.2%; specificity 90.6%). Conclusions In 96 patients with suspected interstitial lung disease, the Envisia Genomic Classifier identified UIP regardless of HRCT pattern. These results suggest that recognition of a UIP pattern by the Envisia Genomic Classifier combined with HRCT and clinical factors in a multidisciplinary discussion may assist clinicians in making an interstitial lung disease (especially IPF) diagnosis without the need for a surgical lung biopsy.
Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events
Kunchok, Amy , Aksamit, Allen J. , Davis, John M. , Kantarci, Orhun H. , Pittock, Sean J. , Weinshenker, Brian G. , Pittock, S J , Weinshenker, Brian G , Pittock, Sean J , Davis, John M , Keegan, B. Mark , McKeon, Andrew

Mayo Clinic

JAMA Neurology | May 18, 2020 | Volume: 77 | Issue: 8 | Pages: 937

10.1001/jamaneurol.2020.1162 | PMID 32421186 Get It